ESMO 2024 – Regeneron's fianlimab do-over
Response rates in a key group shrink from 62% to 39% as the company blames a “clerical error”.
Looking for an ivonescimab encore
What similarly acting projects are still unpartnered?
ESMO 2024 – changing FDA stance could haunt Astra’s Niagara win
Niagara looks sound, but how much benefit did Imfinzi contribute to each of its two settings?
ESMO 2024 – a role for immunotherapy in ovarian cancer
If the therapeutic window remains open, OncoC4/BioNTech’s gotistobart could hold promise.
ESMO 2024 – Opdualag comes under fire
Relativity-104 is revealed as a failure, and the phase 3 it just spawned could fail too.
ESMO 2024 – Incyte tries again in anal cancer
Having failed to get Zynyz approved in the second-line setting the group has the front line in its sights.
ESMO 2024 – iTeos TIGIT meets its efficacy criteria
But the Galaxies Lung-201 trial features notable omissions, plus toxicity.
